Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial
Clinical TherapeuticsPublished 1 January 2003
Reinhard Sittl
Citations186
SJR quartileQ1
SJR score0.98
SNIP1.02
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Buprenorphine TDS was shown to be an effective analgesic against chronic, severe pain in this study population and showed improved duration of sleep and reduced need for additional oral analgesics.
Abstract
Buprenorphine TDS was shown to be an effective analgesic against chronic, severe pain in this study population. Patients treated with this new formulation of buprenorphine showed improved duration of sleep and reduced need for additional oral analgesics.
Keywords
Medicine
Statistical Methods in Cancer Research
6,727 Citations1980N. E. Breslow
PainValidation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study
1,009 Citations1995D. Zech, Stefan Grond +3 more
The results emphasise once again the marked efficacy and low rate of complications associated with oral and parenteral analgesic therapy as the mainstay of pain treatment in the palliative care of patients with adBANced cancer.
PainLack of analgesic effect of opioids on neuropathic and idiopathic forms of pain
991 Citations1988Staffan Arnér, Björn A. Meyerson
The outcome of the double‐blind opioid test has proved useful to justify a continued, or discontinued, use of narcotic medication in individual patients and may also support the indication and choice of invasive stimulation procedures (spinal cord or brain).
Journal of Pain and Symptom ManagementEquianalgesic Dose Ratios for Opioids
532 Citations2001José Pereira, Peter G. Lawlor +3 more
A systematic search of published literature from 1966 to September 1999 was conducted to critically appraise the emerging evidence on equianalgesic dose ratios derived from studies of chronic opioid administration, finding major findings that have important clinical implications for clinicians and warrant consideration in the potential revision of current tables.
Journal of Pain and Symptom ManagementOpioid therapy for chronic nonmalignant pain: a review of the critical issues
529 Citations1996Russell K. Portenoy
It is suggested that there is a subpopulation of patients with chronic pain that can achieve sustained partial analgesia from opioid therapy without the occurrence of intolerable side effects or the development of aberrant drug-related behaviors.
Journal of Pain and Symptom ManagementTransdermal fentanyl versussustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life
476 Citations1997Sam H. Ahmedzai, David Brooks
Transdermal fentanyl provided pain relief that was acceptable to cancer patients and was associated with less constipation and sedation than morphine, which reduced side effects may contribute to patients preference for the patches.
DrugsBuprenorphine
400 Citations1979R.C. Heel, R.N. Brogden +2 more
Buprenorphine appears to produce side effects which are similar to those seen with other morphine- like compounds, including respiratory depression, and animal studies and a direct addiction study in a few volunteers suggest that the dependence liability of buprenorphines may be lower than that of other older morphine-like drugs.
Journal of Pain and Symptom ManagementLong-term oral opioid therapy in patients with chronic nonmalignant pain
365 Citations1992M. Zenz, M. Strumpf +1 more
It is indicated that opioids can be effective in chronic nonmalignant pain, with side effects that are comparable to those that complicate the treatment of cancer pain.
BMJRandomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain
302 Citations2001L. Allan, Helen Hays +5 more
Transdermal fentanyl was preferred to sustained release oral morphine by patients with chronic non-cancer pain previously treated with opioids, and better pain relief was achieved with less constipation and an enhanced quality of life.
Journal of Pharmacology and Experimental TherapeuticsAcute administration of buprenorphine in humans: partial agonist and blockade effects.
283 Citations1995Sharon Walsh, Kenzie L. Preston +2 more
There is a ceiling on the effects of buprenorphine in humans that may reduce its abuse liability and increase its safety, and indicate that opioid blockade occurs after acute administration of bu p.o.m. or methadone.
Statistics in MedicineMultiple testing in clinical trials
240 Citations1991Péter Bauer
The main emphasis is on the concept of the multiple level of significance (controlling the experiment, or family error in the strong sense) which can be achieved by applying the principle of closed tests.
Clinical PharmacokineticsClinical Pharmacokinetics of Transdermal Opioids
233 Citations2000Stefan Grond, Lukas Radbruch +1 more
In cancer pain, TTS fentanyl offers an interesting alternative to oral morphine, and its effectiveness and tolerability in this indication has been demonstrated by a number of trials, while its usefulness in chronic pain of nonmalignant origin remains to be confirmed in controlled trials.
The Journal of Clinical Endocrinology & MetabolismA Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Transdermal Dihydrotestosterone Gel on Muscular Strength, Mobility, and Quality of Life in Older Men with Partial Androgen Deficiency
230 Citations2001Lam P Ly, Mark Jimenez +4 more
It is concluded that 3 months treatment with transdermal dihydrotestosterone gel demonstrates expected androgenic effects, short-term safety, and limited improvement in lower limb muscle strength but no change in physical functioning or cognitive function.
Journal of Clinical OncologyQuality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine.
228 Citations1998Richard Payne, Susan D. Mathias +4 more
Comparing pain-related treatment satisfaction, patient-perceived side effects, functioning, and well-being in patients with advanced cancer who were receiving either transdermal fentanyl or sustained-release oral forms of morphine suggests that patients are more satisfied with transDermal fentanyl compared with sustained- release oral formsof morphine.
NeuropharmacologyBuprenorphine has potent kappa opioid receptor antagonist activity
139 Citations1987Jacob Leander
Buprenorphine was a potent antagonist of bremazocine-induced urination and had no kappa agonist activity, indicating the high affinity that buprenorphines has for the kappa receptor results in potent kappa receptors antagonist activity in vivo.
Clinical PharmacokineticsPharmacokinetic Characterisation of Transdermal Delivery Systems
127 Citations1994Bret Berner, V. A. John
Transdermal delivery systems, designed on the basis of pharmacokinetic principles and concentration-effect relationships, have the potential to provide optimal therapy for the treatment of some conditions.
DrugsTreatment Principles for the Use of Opioids in Pain of Nonmalignant Origin
113 Citations1991Stephan A. Schug, Alan Merry +1 more
With sensible guidelines, and in the context of a multidisciplinary pain clinic, opioids may provide the only hope of relief to many sufferers of chronic pain.
PainTransdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients
107 Citations1992D. Zech, Stefan Grond +4 more
The use of TTS fentanyl in combination with initial dose titration using PCA gave rapid and statistically significant pain relief and may indicate that conversion ratios from intravenous to transdermal administration should be increased or that TTS should be changed earlier.
Molecular PharmacologyAgonistic Effect of Buprenorphine in a Nociceptin/OFQ Receptor-Triggered Reporter Gene Assay
95 Citations1999Stephan Wnendt, Thomas M. Krüger +3 more
A reporter gene assay has been established in which the ORL1 receptor is functionally linked to the cyclic AMP-dependent expression of luciferase, and there is a need for antagonistic tool compounds that might help to elucidate the neurophysiological role of N/OFQ.
The American Journal of CardiologyAcute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin
89 Citations1991Steering Committee
The study showed that tolerance to the exercise effects of continuous transdermal nitroglycerin develops within 24 hours after application and increasing the dose does not overcome this tolerance, and the observation that symptomatic improvement may occur in the absence of increases in exercise tolerance seems deserving of further study.
JAMATransdermal Fentanyl for Postoperative Pain Management
87 Citations1989Robert A. Caplan
The incidence of vomiting, respiratory rate, and respiratory rate in the active group was lower than in the placebo group during the 13- to 24-hour interval of system application, and transdermal fentanyl appears to be safe and effective after orthopedic surgery in healthy adult patients.
Clinical PharmacokineticsClinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs
84 Citations1983Roy Bullingham, H J McQuay +1 more
Pentazocine, buprenorphine, nalbuphine and butorphanol all demonstrate definite analgesic properties, and naltrexone, in contrast, has only limited agonist action, and is perhaps better regarded as an antagonist.
Annals of PharmacotherapyOpioid Dependence Treatment, Including Buprenorphine/Naloxone
75 Citations2002Dennis W. Raisch, Carol L. Fye +2 more
Buprenorphine combined with naloxone represents an innovative treatment for OD in outpatient settings that has advantages over MMT and pharmacologic modalities used to treat OD.
Anti-Cancer DrugsTransdermal fentanyl therapy: system design, pharmacokinetics and efficacy
65 Citations1995Mary Southam
Four transdermal fentanyl systems are available, providing delivery rates ranging from 25-100 micrograms/h; higher rates can be achieved by multiple system application, and clinical trials have established the efficacy and safety of transDermal fentanyl for the treatment of cancer pain.
Journal of the American College of CardiologyEffect of Transdermal Nitroglycerin or N-Acetylcysteine, or Both, in the Long-Term Treatment of Unstable Angina Pectoris
59 Citations1997Diego Ardissino, Piera Angelica Merlini +9 more
The combination of nitroglycerin and N-acetylcysteine, associated with conventional medical therapy in the long-term treatment of patients with unstable angina, reduces the occurrence of outcome events, but the high incidence of side effects limits the clinical applicability of this therapeutic strategy.
American Journal of Obstetrics and GynecologyClinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy
53 Citations1995Stephen Gordon
European Journal of PainTransdermal fentanyl for pain control in adults with chronic cancer pain
38 Citations1998Ulf E. Kongsgaard, P. Poulain
TTS‐fentanyl appeared to be well tolerated, with a low incidence of constipation, somnolence and nausea, and was not possible to show fentanyl to be statistically superior to placebo at the 5% significance level.
PubMedOral tramadol and buprenorphine in tumour pain. An Italian multicentre trial.
33 Citations1996Fulvio Brema, Grazia Maria Giovanna Pastorino +6 more
In both the short term and in the longer term, it was found that the levels of efficacy and acceptability were always significantly better in the tramadol group than in the buprenorphine group.
Current Medical Research and OpinionAn open study of sub-lingual buprenorphine in the treatment of chronic pain in the elderly
30 Citations1986M A Nasar, M. A. McLeavy +1 more
There was significant improvement in symptoms during the treatment period and the drug was well tolerated, with good compliance, and patients aged over 80 years responded comparatively better than those aged between 65 and 80 years.
Drug and Alcohol DependenceThe clinical usefulness of agonist-antagonistic opioid analgesics in chronic pain
23 Citations1987G.W. Hanks
Buprenorphine is the most useful of the agonist-antagonists in chronic pain patients and is potent, long-acting and effective when given sublingually, however, it has a limited effective dose range and produces the same side effects as morphine-like drugs, possibly more frequently at equianalgesic doses.
Journal of International Medical ResearchSublingual Buprenorphine versus Oral Dihydrocodeine in Post-Operative Pain
22 Citations1981A.H.B. MASSON
Patients experiencing post-operative pain following general surgery were compared with oral dihydrocodeine and there was evidence that buprenorphine had a slightly slower onset of action, but a distinctly longer duration ofaction, than dihydROcodeine.
PubMed[Postoperative on-demand analgesia with buprenorphine].
18 Citations1988Lehmann Ka, B Gördes
Patient-controlled analgesia (PCA) was studied during the early postoperative period and the effectiveness of PCA was judged superior by about 93% of patients when compared with previously experienced postoperative analgesia.